JP2017528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528454A5
JP2017528454A5 JP2017511933A JP2017511933A JP2017528454A5 JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5 JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
pharmaceutical composition
composition according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017511933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528454A (ja
Filing date
Publication date
Priority claimed from US14/473,339 external-priority patent/US9890200B2/en
Application filed filed Critical
Publication of JP2017528454A publication Critical patent/JP2017528454A/ja
Publication of JP2017528454A5 publication Critical patent/JP2017528454A5/ja
Pending legal-status Critical Current

Links

JP2017511933A 2014-08-29 2015-08-28 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法 Pending JP2017528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/473,339 2014-08-29
US14/473,339 US9890200B2 (en) 2011-04-12 2014-08-29 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
PCT/US2015/047390 WO2016033432A1 (en) 2014-08-29 2015-08-28 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (2)

Publication Number Publication Date
JP2017528454A JP2017528454A (ja) 2017-09-28
JP2017528454A5 true JP2017528454A5 (enExample) 2018-10-04

Family

ID=52583553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511933A Pending JP2017528454A (ja) 2014-08-29 2015-08-28 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法

Country Status (12)

Country Link
US (2) US9890200B2 (enExample)
EP (1) EP3185883A4 (enExample)
JP (1) JP2017528454A (enExample)
KR (1) KR20170044171A (enExample)
CN (1) CN107073075A (enExample)
AU (1) AU2015308761A1 (enExample)
BR (1) BR112017003731A2 (enExample)
CA (1) CA2958085A1 (enExample)
MX (1) MX2017002476A (enExample)
RU (1) RU2017110093A (enExample)
SG (1) SG11201701135WA (enExample)
WO (1) WO2016033432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
JP2018512401A (ja) * 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Mk2阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
CN112920256B (zh) * 2019-11-21 2022-08-19 上海医药工业研究院 一种治疗哮喘的生物肽及其应用
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
EP0745063B1 (en) * 1994-02-17 1999-03-24 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DE60026982T2 (de) 1999-04-05 2006-11-16 Mannkind Corp., Danbury Verfahren zur bildung von feinem pulver
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
AU2003223718B2 (en) 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
WO2004009776A2 (en) 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. TREATMENT OF TNFα RELATED DISORDERS
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (enExample) 2006-02-22 2015-07-10 Mannkind Corp
EP2010153A2 (en) * 2006-04-03 2009-01-07 Teva Pharmaceutical Industries Limited Drug microparticles
AU2007342674B2 (en) 2007-01-10 2013-09-19 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008098096A1 (en) 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation キナーゼ阻害薬およびその使用
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Similar Documents

Publication Publication Date Title
JP2014533235A5 (enExample)
RU2013150249A (ru) Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса
JP2017528454A5 (enExample)
JP6889201B2 (ja) Il−4および/またはil−13のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法
JP2018501201A5 (enExample)
US20130216608A1 (en) Airway Administration of Angiogenesis Inhibitors
JP2014169332A (ja) 肺疾患を処置するためのモノクローナル抗体の霧状化
JP2002539072A5 (enExample)
JP2017509633A5 (enExample)
JP2015505303A5 (enExample)
JP2022500078A5 (enExample)
JP2016516016A5 (enExample)
RU2017110093A (ru) Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса
JP2010539243A (ja) 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのlight阻害剤
JP2004500844A (ja) Tweakアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法
Li et al. Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
CN106905427A (zh) 用于抑制炎症的肽
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
CN106075401A (zh) 白介素35在制备治疗自身免疫性皮肤病药物中的用途和治疗药物以及IL‑35‑Fc融合蛋白
RU2016140332A (ru) Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл)
WO2011113024A1 (en) Compositions and methods for healing of skin wounds
JP2002515459A (ja) 喘息および他のアレルギー性症状を治療するための方法およびtnf−rii(p75)アゴニストを含む組成物の使用
Laurina et al. Growth factors/cytokines/defensins and apoptosis in periodontal pathologies
CN117209612A (zh) 融合蛋白及其应用